CytoReason, a leader in developing computational disease models for predictive insights, announced it has secured $80 million in funding from prominent investors such as OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific. This investment will support CytoReason’s plans to extend the application of its models to new indications, expand its proprietary molecular and clinical data, and establish a new office in Cambridge, Massachusetts later this year.
CytoReason’s technology aims to reduce R&D timelines and improve the probability of technical and regulatory success (PTRS) in the life sciences sector. By providing therapeutic area leaders with molecular-level insights and advanced AI tools, the company enhances data-driven decision-making processes, thereby optimizing R&D portfolios and increasing the likelihood of phase 2 success. Since expanding its partnership with Pfizer in 2022, CytoReason has added three major pharmaceutical partnerships and extended its disease model coverage to central nervous system (CNS)-related diseases.
The company's scientific contributions are frequently published in prestigious journals such as Nature, Cell, and Gut. In 2023 alone, CytoReason’s scientists published 20 peer-reviewed articles across 16 journals, showcasing the high scientific throughput of their team. With six of the world’s top ten pharma companies utilizing CytoReason’s technology in areas like immunology, inflammation, and immuno-oncology, the company is well-positioned to further revolutionize pharma R&D. The new funding will accelerate CytoReason’s growth, enabling more pharmaceutical and biotech companies to enhance the speed and accuracy of their asset development processes, ultimately benefiting patients worldwide.
Click here to read the original news story.